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Objectives: Cardiopulmonary bypass is associated with the release of proinflam-
matory cytokines (tumor necrosis factor , interleukin 1, interleukin 6, and
interleukin 8) and anti-inflammatory cytokines (interleukin 10 and transforming
growth factor 1). On the one hand this cytokine release is related to the postop-
erative systemic inflammatory response syndrome, and on the other hand it is related
to deterioration of the immune system, for example in monocyte or polymorpho-
nuclear neutrophil function, leading to an increased susceptibility to infections. To
gain further insight into the alterations of immune cell reactivity and possible
regulatory mechanisms, we studied lipopolysaccharide-induced tumor necrosis fac-
tor  synthesis in whole blood from cardiac surgical patients.
Methods: Fifteen patients undergoing elective heart surgery with cardiopulmonary
bypass were included in the study. Ex vivo lipopolysaccharide-induced tumor
necrosis factor  synthesis was measured in a whole blood assay before, during, and
after bypass. Corresponding tumor necrosis factor  messenger RNA levels were
determined by semiquantitative reverse transcriptase-polymerase chain reaction. In
addition, the influence of patient serum on whole blood responsiveness and its
relationship to anti-inflammatory cytokines were evaluated in vitro.
Results: Tumor necrosis factor  synthesis was significantly reduced after 30
minutes of cardiopulmonary bypass and showed the lowest values at the end of
bypass (mean  SD 0.109  0.105 ng/106 white blood cells after 30 minutes of
bypass and 0.050 0.065 ng/106 white blood cells at the end of bypass, vs 0.450
0.159 ng/106 white blood cells preoperatively, P  .001). As a further indication of
reduced cytokine biosynthesis, diminished messenger RNA levels for tumor necro-
sis factor  were detected. Serum withdrawn from patients at the end of cardiopul-
monary bypass reduced tumor necrosis factor  synthesis in heterologous blood
from healthy volunteers highly significantly to 39.93% 23.18% relative to control
serum (P  .005) and preoperatively drawn serum (P  .024). This effect was dose
From the Department of Cardiac and Tho-
racic Surgerya and the Institute of Medical
Epidemiology, Biometrics, and Informat-
ics,b Martin-Luther-University Halle-Wit-
tenberg, Halle/Saale, and the Department of
Surgery, Clinical Research Group Shock &
MOF,c University Hospital of Essen, Essen,
Germany.
Supported by grants from the Deutsche
Forschungsgemeinschaft (Schm 74/ 13-2),
IFORES University of Essen (J.B.), and
Fonds der Chemischen Industrie (F.U.S.).
Received for publication April 28, 2001;
revisions requested June 22, 2001; revi-
sions received Nov 28, 2001; accepted for
publication Dec 12, 2001.
Address for reprints: Jochen Bo¨rgermann,
MD, Martin-Luther-University Halle-Wit-
tenberg, Department of Cardiac and Tho-
racic Surgery, Ernst-Grube-Str 40, 06120
Halle/Saale, Germany (E-mail:
Jochen.Boergermann@t-online.de).
J Thorac Cardiovasc Surg 2002;124:608-17
Copyright © 2002 by The American Asso-
ciation for Thoracic Surgery
0022-5223/2002 $35.000 12/1/122300
doi:10.1067/mtc.2002.122300
608 The Journal of Thoracic and Cardiovascular Surgery ● September 2002
CSP
dependent and was not specific for lipopolysaccharide-induced tumor necrosis
factor  synthesis. Anesthesia and heparin administration did not influence tumor
necrosis factor  production significantly. Ex vivo tumor necrosis factor  synthesis
was negatively related to interleukin 10 serum levels, positively but weakly related
to interleukin 4, and was not related to transforming growth factor 1 (Spearman
correlation coefficients 0.565, P  .001, 0.362, P  .001, and 0.062, P  .460,
respectively). However, interleukin 10 levels in patient serum after cardiopulmonary
bypass were 300-fold below the quantities needed for half-maximal inhibition of
tumor necrosis factor  synthesis in vitro. Moreover, the inhibitory activity could
not be removed by immune absorption of interleukin 10.
Conclusions: These results suggest that during cardiac operations cytokine-inhibi-
tory serum activities are released or newly formed. These activities could not be
explained by the actions of interleukins 4 and 10 or transforming growth factor 1.
Although their exact nature remains undetermined, these substances may contribute
to the diminished immune cell functions after cardiopulmonary bypass and thus
need further characterization.
Cardiac surgery, in particular with cardiopul-monary bypass (CPB), is associated with awide variety of adverse physiologic andimmunologic effects. Surgical trauma,ischemia-reperfusion, endotoxemia, andactivation of monocytes by artificial sur-
faces are the predominant mechanisms that trigger the post-
operative systemic inflammatory response syndrome.1,2 Key
cells in the inflammatory processes, such as systemic in-
flammatory response syndrome and sepsis, are polymorpho-
nuclear neutrophils. When activated, these cells release var-
ious inflammatory mediators, such as eicosanoids,
proteolytic enzymes, oxygen radicals, and cytokines. Poly-
morphonuclear neutrophil reactivity is modulated by di-
verse cytokines. It has been shown that proinflammatory
and anti-inflammatory cytokines are released during CPB.3-7
Whereas proinflammatory cytokines (such as tumor necro-
sis factor [TNF] , interleukin [IL] 1, IL-6, and IL-8) alter
myocardial contractility, peripheral circulation, and other
organ functions,8,9 anti-inflammatory cytokines (such as
IL-4, IL-10, and transforming growth factor 1 [TGF-1])
may play a role in the deterioration of the immune system
after CPB.10,11 On the other hand, anti-inflammatory cyto-
kines are believed to limit complications induced by an
overshooting proinflammatory reaction. It is therefore be-
lieved that the balance of proinflammatory and anti-inflam-
matory mediators is of crucial importance for an adequate
host reaction to insults associated with systemic inflamma-
tory response syndrome. Under conditions of polytrauma
and sepsis, dysregulation of in vitro cytokine synthesis by
isolated monocytes or whole blood has been shown to be
associated with the clinical outcome or the extent of trau-
ma.12,13 To our knowledge only a few studies have investi-
gated cytokine synthesis in the blood compartment in pa-
tients undergoing CPB.14 This study was therefore designed
to evaluate cytokine synthesis and its regulatory mecha-
nisms in whole blood after CPB. The whole blood system
was chosen rather than isolated peripheral blood mononu-
clear cells to minimize artifacts arising from cell isolation or
the lack of cells and humoral factors involved in the periph-
eral blood mononuclear cell response in their natural envi-
ronment.15
Patients and Methods
Patients
After approval by the ethics committee of our faculty, 15 patients
scheduled to undergo elective cardiac surgery with CPB were
enrolled in this prospective study. Patients with autoimmune dis-
eases, those with hepatic or renal dysfunction, and patients receiv-
ing steroids or nonsteroidal anti-inflammatory drugs were ex-
cluded. All patients provided written, informed consent. In all
cases the outcome was uneventful. Biometric, clinical, and peri-
operative data of the 15 patients are summarized in Table 1.
Anesthesia and CPB Technique
Aspirin was stopped 7 days before the scheduled date of surgery,
and antianginal substances were continued until the day of oper-
ation. Premedication consisted of flunitrazepam (25-30 g/kg
body weight orally) for night sedation, with another dose 2 hours
before induction of anesthesia. Perioperatively, the following pa-
rameters were monitored: electrocardiogram, central venous pres-
sure, pulmonary artery pressure, and arterial pressure. Body tem-
perature was monitored continuously. Anesthesia was induced
with etomidate (0.2-0.4 mg/kg body weight), sufentanil (2-4 g/kg
body weight), and pancuronium bromide (0.1 mg/kg body weight).
Patients were endotracheally intubated and mechanically venti-
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lated with oxygen and air (inspired oxygen fraction 0.5) to main-
tain a PaCO2 of 35 to 40 mm Hg or an end-tidal carbon dioxide
level of 4.5% to 5.0%. Balanced anesthesia was maintained with
sufentanil and isoflurane (0.5%-1.0% volume percentage).
The CPB technique was standardized with a roller pump
(Sto¨ckert Instrumente GmbH, Munich, Germany), a flat sheet
membrane blood oxygenator (COBE CML Duo; COBE Cardio-
vascular, Heimstetten, Germany) and identical priming solution
for all patients. Cardioplegia was induced by antegrade application
of cooled Bretschneider solution (Custodiol; Dr F. Ko¨hler Chemie,
Alsbach-Ha¨hnlein, Germany) into the aortic root. Nonpulsatile
blood flow during CPB was 2.5 L/(min  m2 body surface area),
and conditions were mildly hypothermic (35°C). The administra-
tion of heparin for cannulation and antagonization with protamine
sulfate were performed in a standardized fashion. After the oper-
ation, pharmacologic support was instituted according to hemody-
namic requirements.
Blood Sampling
Blood was withdrawn at 11 time points from the central venous
line and collected in plastic tubes (ammonium heparin [9 mL] and
serum [9 mL]; Sarsted Monovette; Nu¨mbrecht, Germany). After
sampling, whole blood was immediately prepared for ex vivo
endotoxin stimulation. Serum samples were allowed to clot, cen-
trifuged (3.500 rpm for 10 minutes), and the separated serum was
frozen at 80°C until assay. Time points of blood sampling were
as follows: T1, 8:00 AM, day of operation, before anesthesia; T2,
after induction of anesthesia; T3, after administration of heparin;
T4, 30 minutes after start of CPB; T5, 5 minutes after unclamping
of the aorta; T6, at the end of CPB; T7, 4 hours after CPB; T8, first
postoperative day, 8:00 AM; T9, second postoperative day, 8:00
AM; T10, fourth postoperative day, 8:00 AM; and T11, sixth post-
operative day, 8:00 AM.
Ex Vivo Endotoxin Stimulation of Whole Blood
Whole blood was mixed 1:1 (volume/volume) with cell culture
medium (RPMI 1640; Gibco-BRL, Eggenstein, Germany) contain-
ing 64-IU/mL penicillin, 64-g/mL streptomycin, and 20-mmol/L
sodium hydrogen carbonate). Mixtures were set up in flat-bot-
tomed 24-well plates (Falcon 3072 Microtest III tissue culture
tube; Becton Dickinson, Heidelberg, Germany) in a total volume
of 800 L. Samples were prepared in triplicate. Cultures were
incubated with (100 ng/mL) and without endotoxin (lipopolysac-
charide from Salmonella friedenau, kindly provided by Dr Brade,
Forschungszentrum Borstel, Borstel, Germany) for 4 hours at 37°C
in a 5% carbon dioxide, water-saturated atmosphere. Supernatants
were collected after centrifugation and stored at 80°C until
cytokine determination. The cell pellets were lysed with 0.05-
mol/L guanidinium thiocyanate buffer for RNA isolation.
Total and differential white blood cell (WBC) counts were
obtained for each blood sample with a Coulter counter (Coulter,
Krefeld, Germany).
Bioassay for TNF--Inhibitory Capacity
Heterologous whole blood from healthy volunteers was incubated
with endotoxin (10 ng/mL) in the presence of additional patient
serum withdrawn before the operation with CPB, after the opera-
tion, and on the sixth postoperative day, as described previously.
An equal amount of autologous donor serum served as control. The
reduction in endotoxin-stimulated TNF- secretion reflected the
inhibitory capacity of the serum. The inhibitory capacity is ex-
pressed as percentage of the TNF- production in whole blood
cultures incubated in the presence of autologous donors serum.
Enzyme-Linked Immunosorbent Assays
Levels of cytokines in the supernatants of whole blood cultures
and patient serum were measured with specific enzyme-linked
immunosorbent assays (ELISAs). TNF- concentration was deter-
mined with a monoclonal antihuman TNF- antibody (Genzyme,
Munich, Germany), a polyclonal antihuman TNF- antiserum
raised in rabbits, and a horseradish peroxidase-conjugated goat
antirabbit immunoglobulin G serum (Dianova, Hamburg, Ger-
many) as a detection system. For standards, recombinant human
TNF- (Genzyme) was used. All samples and standards were
assayed in triplicate. Mean values for each were used in calculating
sample concentrations through a linear regression analysis of the
optical density (micro-ELISA autoreader Dynatech MR 5000 [Ac-
terna Corporation, Deukendorf, Germany], test filter 405 nm,
reference filter 490 nm) versus the TNF- concentration on the
standard curve. For the standard of each plate, r2 was greater than
0.95. The lower detection limit for the TNF- ELISA was 30
pg/mL. Results of measurements in the supernatants of whole
blood cultures were additionally normalized to represent nano-
grams per 106 WBCs.
Serum levels of IL-4, IL-10, and TGF-1 were determined with
commercially available ELISA kits according to the manufacturer
guidelines (IL-4 and IL-10 from Biomedia, Baesweiler, Germany;
TGF-1 from Genzyme). Acidification of serum samples for mea-
surements of total TGF-1 was performed according to the man-
ufacturer instructions. All samples and standards were assayed in
duplicate. No adjustment was made for hemodilution. Lower de-
tection limits were 1.5 pg/mL for IL-4, 3 pg/mL for IL-10, and 50
pg/mL for TGF-1.
TABLE 1. Biometric, clinical, and perioperative data (n 
15)
Sex ratio (male/female) 8:7
Age (y, mean  SD) 64.53 9.21
New York Heart Association functional
classification (mean  SD)
2.47 0.64
Procedure
Coronary artery bypass grafting 11
Aortic valve replacement 2
Coronary artery bypass grafting plus aortic
valve repalcement
2
Operative time (min, mean  SD) 207.87 57.06
CPB time (min, mean  SD) 97.07 44.18
Crossclamp time (min, mean  SD) 58.80 26.90
Central temperature (°C, mean  SD) 34.94 0.67
Intensive care unit stay (h, mean  SD) 30.93 24.71
Intubation time (h, , mean  SD) 14.14 5.23
Blood loss over chest drain (mL, mean  SD) 552.31 347.83
Transfused packed red blood cells (units,
mean  SD)
2.14 1.46
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Bioassay of TNF
TNF bioactivity was determined in a cytolytic cell assay in the
mouse fibrosarcoma cell line WEHI 164, clone 13 (gift of Dr
Espevik, Institute of Cancer Research, University of Trondheim,
Norway), as described previously.16 In brief, WEHI cells (2 
104cells/well) were incubated with serial dilutions of supernatants
in microtiter plates. After 18 hours, 10% 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium-bromide (MTT 5 mg/mL in phos-
phate-buffered saline solution; Sigma Deisenhofen, Germany) was
added. The reaction was stopped after 4 hours by addition of 5%
formic acid in isopropanol (Merck, Darmstadt, Germany), and the
content of reduced MTT was read in a micro-ELISA autoreader
(MR 5000, test filter 570 nm, reference filter 660 nm; Dynatech).
The titer of TNF, which is expressed in units per milliliter, was
chosen as the reciprocal of the dilution necessary to cause 50% cell
lysis.16 The specificity of this bioassay was tested by adding an
antiserum against TNF- (Genzyme) to the supernatants. It was
found to neutralize more than 90% of the cytolytic activity mea-
sured with the WEHI assay.
Immune Absorption of IL-10
Aliquots of 300 L of patient serum were mixed 1:1 (volume/
volume) with medium (RPMI; Gibco-BRL) and incubated over-
night at 4°C with 35 L protein G-Sepharose (Pharmacia,
Freiburg, Germany) already swollen in phosphate-buffered saline
solution and 50 L of antihuman IL-10 antibody (Biozol GmbH,
Eching, Germany), antihuman HLA-DR antibody (isotype control;
Becton Dickinson, Heidelberg, Germany), or phosphate-buffered
saline solution. After centrifugation, supernatants were tested in
the bioassay for TNF--inhibitory capacity and the IL-10 ELISA.
RNA Isolation, Complementary DNA Synthesis, and
Semiquantitative Reverse Transcriptase-Polymerase
Chain Reaction
Total RNA was isolated from cell pellets of the endotoxin-stimu-
lated whole blood by acid guanidinium thiocyanate-phenol-chlo-
roform extraction and further by a commercial RNA preparation
kit (RNeasy Total RNA Kit; QIAGEN, Du¨sseldorf, Germany)
according to the manufacturer instructions. The amount and the
purity of RNA were quantified by measuring the optical density at
260 and 280 nm with a Beckmann spectrophotometer (Pharmacia,
Cambridge, United Kingdom). Approximately 1 g of total RNA
was reverse transcribed with Moloney murine leukemia virus
reverse transcriptase (Superscript; Gibco-BRL), 25 pmol oligode-
oxythymidine primer, 0.1-mol/L dithiothreitol, and 10-mol/L
each nucleoside triphosphate (Perkin-Elmer, Weiterstadt, Ger-
many) in a total volume of 20 L. For further processing, the
complementary DNA (cDNA) was diluted 1:5 with deionized
water and stored at 80°C.
Polymerase chain reaction (PCR) was carried out as reported in
detail elsewhere.17 In brief, PCR was performed with different
amounts of cDNA, 200 pmol of each primer (Eurogentec, Ko¨ln,
Germany), 0.2 mol deoxynucleoside triphosphate, and 1 unit Taq
DNA polymerase (Roche Diagnostics GmbH, Mannheim, Ger-
many) in a total volume of 100 L. Reaction mixtures were placed
in a thermocycler (Gene Amp PCR System 2400; Perkin-Elmer,
Weiterstadt, Germany), and each PCR cycle consisted of the
following: denaturation (30 seconds at 95°C), primer annealing
(30 seconds at 50°C for -actin and at 56°C for TNF), and DNA
extension (45 seconds at 72°C). Primer sequences, cDNA
amounts, and cycle numbers are shown in Table 2. PCR for each
product was performed separately at four cDNA concentrations
and a minimum of cycles to yield an amplificate, so that the
amounts of the amplificates reflect the quantities of the cDNA and
messenger RNA (mRNA) present in the preparation. Amplificates
were quantified after separation on a 1.5% agarose gel with
ethidium bromide fluorescence analysis (Fluorimager; Molecular
Dynamics, Krefeld, Germany). PCRs were accepted as quantita-
tive if fluorescence intensities of amplificates after linear regres-
sion versus cDNA dilutions resulted in a linear relationship (r 
0.95). All measured PCR products were calculated on the amount
of 1 L cDNA and normalized to the amount -actin in each
sample.
Statistical Analysis
Results are presented as mean  SD. For statistical analysis we
used nonparametric methods (signed rank test, Wilcoxon test,
nonparametric analysis of variance, Spearman correlation coeffi-
cient) whenever possible. All analyses if necessary accounted for
the fact that measurements were repeatedly taken from the same
patients. Pairwise comparisons analyses were Bonferroni ad-
justed to avoid spurious significances. Calculations were per-
formed with SAS version 8e statistical software (SAS Institute,
Inc, Cary, NC).
Results
Ex Vivo TNF- Synthesis in Whole Blood
Lipopolysaccharide-induced TNF- release of isolated
whole blood obtained from patients before the operation
TABLE 2. Primer sequences, cDNA amounts, and cycle numbers
Primer Sequence cDNA (L) Cycles
-Actin
Sense 5-TGAAGTCTGACGTGGACATC-3 0.125-1.0 25; 27
Antisense 5-ACTCGTCATACTCCTGCTTG-3
TNF-
Sense 5-CAGAGGGAAGAGTTCCCCAG-3 0.25-2.0 35; 37
Antisense 5-CCTTGGTCTGGTAGGAGACG-3
Primers were exon-intron overspanning or included an intron to rule out contamination of chromosomal DNA.
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with CPB, during the operation, and at serial time points
until the sixth postoperative day was studied. After stimu-
lation with endotoxin (100 ng/mL), release of TNF- could
be observed in all patients at all time points (Figure 1, A).
Because activated monocytes as well as granulocytes and
lymphocytes represent potential sources of cytokines, and to
exclude artifacts arising from hemodilution or intraopera-
tive blood loss during CPB, TNF- production was normal-
ized to white blood cell counts. Ex vivo TNF- synthesis
was significantly reduced after 30 minutes of CPB and
showed the lowest value at the end of CPB (mean  SD
0.109  0.105 ng/106 WBC after 30 minutes of CPB [T4]
and 0.050  0.065 ng/106 WBC at the end of CPB [T6] vs
0.450  0.159 ng/106 WBC before operation [T1], P 
.001). When TNF- bioactivity measured by WEHI assay
was compared with total TNF- determined by ELISA, a
highly significant correlation was found (Figure 1, B). The
capacity of whole blood to synthesize TNF- increased
within the next days 3- to 5-fold, but it did not recover
completely within the observation period. Whereas IL-6 and
IL-8 serum levels were found to be increased after CPB in
a way comparable to other studies (peak values at the end of
CPB of 430 pg/mL and 89 pg/mL, respectively),18 no sig-
nificant TNF- release was observed in unstimulated blood
or serum at any of the 11 sampling points.
TNF- Messenger RNA Expression in
Lipopolysaccharide-Stimulated Whole Blood
To gain further insight into the regulation of TNF- syn-
thesis after CPB, mRNA expression in lipopolysaccharide-
stimulated (100 ng/mL) whole blood was studied by reverse
transcriptase-PCR in 6 cases. As shown in Figure 2, a
significant suppression of mRNA expression for TNF- was
found after CPB (mean  SD 21.15%  20.51%, range
7.56%-29.55%) of preoperative TNF- mRNA expression,
P .001). In parallel with the protein concentrations deter-
mined in the supernatants of ex vivo stimulated whole blood
cultures, mRNA expression increased after operation to
approximately 50% of preoperative values. Similar kinetics
of lipopolysaccharide-stimulated cytokine release and
mRNA expression support the hypothesis that the observed
phenomenon is mediated by regulation at a transcriptional
or pretranscriptional step of cytokine synthesis.
TNF--Inhibitory Activity in Patient Serum After
CPB
To test the hypothesis that the impaired ex vivo synthesis of
TNF- is caused by inhibitory substances circulating in
patient serum after CPB, whole blood obtained from healthy
volunteers was incubated with lipopolysaccharide in the
presence of additional patient serum withdrawn before the
operation, at the end of CPB, and on the sixth postoperative
day. Autologous donor serum served as control. As shown
in Figure 3, the addition of patient serum withdrawn at the
end of CPB resulted in a highly significant reduction of
TNF- secretion to 39.93%  23.18% (mean  SD) rela-
tive to control serum (P  .005) and to preoperative serum
(P  .024). Increasing amounts of patient serum withdrawn
after CPB resulted in a dose-dependent inhibition of lipopo-
lysaccharide-stimulated TNF- synthesis, whereas serum
withdrawn before the operation and autologous donor serum
had no marked effect. This finding excludes the possibility
Figure 1. A, Ex vivo TNF- synthesis of endotoxin-stimulated (S
friedenau, 100 ng/mL) whole blood normalized to 1  106 WBCs.
Double asterisk indicates P < .01 versus preoperative values (T1);
triple asterisk indicates P < .001; P values are Bonferroni ad-
justed and calculated as pairwise comparisons within a repeated
measurement nonparametric analysis of variance model. Data
points represent mean for 15 patients from triplicate cultures for
each time point for each patient; error bars represent SD. B,
Comparison between WEHI bioassay and enzyme-linked immu-
nosorbent assay (n  150). High correlation between bioactive
TNF and total TNF- (line) indicates little interference by plasma
proteins such as soluble TNF receptors (Spearman correlation
coefficient r  0.492, P < .001).
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that a deficiency in serum components after CPB (eg,
lipopolysaccharide-binding protein) contributes to the in-
hibited lipopolysaccharide response (Figure 4). Further-
more, when whole blood was activated with heat-killed
streptococci or zymosan, TNF- production was inhibited
to the same degree by serum taken after CPB (data not
shown). It therefore seems unlikely that substances that
interfere with lipopolysaccharide (eg, soluble CD14 or
bactericidal permeability-increasing protein) contribute
to the inhibitory activity in patient serum. A highly signif-
icant correlation (Spearman correlation coefficient
r  0.492, P  .001) between TNF- bioactivity mea-
sured by WEHI assay and TNF- determined by ELISA
indicates no relevant interference by TNF--binding
proteins (Figure 1, B). In addition, when serum containing
the inhibitory activity was added to volunteer whole blood
after incubation with lipopolysaccharide, this did not
diminish TNF- as determined by either ELISA or WEHI
assay. These results suggest that the inhibitory activity is
neither due to substances interfering with lipopolysaccha-
ride nor to substances interfering with the bioactivity of
TNF-.
Influence of Heparin on TNF- Synthesis In Vitro
To investigate whether the suppression of cytokine
synthesis during CPB is related to heparinization, the
effects of increasing doses of heparin were studied in
whole blood in vitro. Whole blood from healthy volun-
teers was incubated with lipopolysaccharide in the
presence or absence of heparin (0.16-100 U/mL)
for 4 hours. It was found that heparin in doses that
exceeded the doses necessary for anticoagulation
during CPB by 10 times did not affect TNF- synthesis
in vitro (Figure 5). This suggests that heparin is not
responsible for decreased TNF- production during and
after CPB.
Figure 3. Inhibition of whole blood TNF- synthesis by patient
serum prepared after CPB. Mixtures contained 100 L (33%)
additional serum and were stimulated with endotoxin (S. friede-
nau, 10 ng/mL). Serum withdrawn at end of CPB caused statisti-
cally significant inhibition of TNF- synthesis in heterologous
whole blood from healthy volunteers relative to preoperative
serum (preop.) or volunteer serum (control). Bar heights represent
mean for 10 independent experiments; error bars represent SD. P
values were calculated by signed rank test if data from same
patient were compared and by Wilcoxon test for comparison with
control. All P values were Bonferroni adjusted.
Figure 2. Analysis of TNF- and -actin mRNA in whole blood after 4 hours of stimulation by endotoxin (S.
friedenau, 100 ng/mL). Left, Agarose gel stained with ethidium bromide of 1 typical patient among 6. Right, Results
of semiquantitative reverse transcriptase-PCR. In parallel with protein secretion, expression of TNF- mRNA was
significantly reduced after CPB to 21.15% 20.51% (range 7.56%-29.55%) of preoperative values and had recovered
to approximately 50% on postoperative day 6. Bar heights represent mean for 6 patients; error bars represent SD.
Asterisk indicates P < .05 versus preoperative values (T1); double asterisk indicates P < .01; triple asterisk
indicates P < .001; P values are Bonferroni adjusted and calculated as pairwise comparisons within a repeated
measurement nonparametric analysis of variance model.
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Relationship Between TNF- Production and Anti-
inflammatory Cytokines in Patient Serum
It has been shown that IL-4, IL-10, and TGF-1 are potent
inhibitors of TNF- synthesis both in vivo and in vitro.
Therefore, the spontaneous releases of these cytokines at the
indicated time points were measured (Table 3).
Mean ( SD) IL-4 levels dropped from 106.90  63.15
pg/mL before the operation to 9.78 10.48 pg/mL after the
administration of heparin (P  .001) and remained at this
very low level until the end of CPB. After the operation the
IL-4 serum concentrations increased continuously, and they
reached preoperative baseline values on the sixth postoper-
ative day.
IL-10 was barely detectable until a rapid release after
unclamping of the aorta, and it peaked at the end of CPB
(241  192 pg/mL after unclamping [T5] and 318  186
pg/mL end of CPB [T6], vs 36 71 pg/mL before operation
[T1], P  .001). Within the next 48 hours, IL-10 progres-
sively declined to preoperative values.
TGF-1 was detectable in all patients at all time points,
with a preoperative baseline value of 17.16  12.30 ng/mL.
At the end of CPB, TGF-1 concentrations increased insig-
nificantly to 22.59  13.15 ng/mL. Afterward there was a
decrease to 8.53  8.35 ng/mL on the first postoperative
day, and the concentrations remained at this level during the
remainder of the observation period.
Spearman correlation analysis between ex vivo lipopo-
lysaccharide-induced TNF- synthesis and anti-inflamma-
tory cytokines in patient serum showed that IL-10 was
negatively correlated with TNF- production in whole
blood (r  -0.565, P  .001), whereas IL-4 showed a weak
positive correlation (r  0.362, P  .001) and TGF-1 was
not related (r -0.062, P .460). However, in vitro studies
revealed that the concentrations of recombinant human
IL-10 needed to cause half-maximal inhibition of TNF-
synthesis in human blood were about 300 times higher than
those found in patient serum after CPB (data not shown). In
addition, as shown in Figure 6, after immune absorption of
IL-10, the inhibitory potential of serum withdrawn at the
end of CPB was not altered.
Discussion
This study was carried out to investigate whole blood re-
sponsiveness to endotoxin stimulation as an indicator of
leukocyte function and its regulatory mechanism after CPB.
It has been well documented that CPB leads both to a
proinflammatory response1,3,8 and to diminished humoral
and cell-mediated immunity.4,19 The resulting attenuation of
immune functions may pave the way for infectious or septic
complications, which primarily contribute to increased mor-
bidity and mortality after major surgery, especially cardiac
surgery. We found a substantially diminished capacity of ex
Figure 4. Dose-dependent inhibition of whole blood TNF- syn-
thesis by patient serum prepared after CPB. Heterologous whole
blood from healthy volunteers was incubated with endotoxin (S.
friedenau, 10 ng/mL) for 4 hours in presence of 1 to 100 L
(0.33%-33%) patient serum taken before operation or at end of
CPB and volunteer serum. Control indicates TNF- synthesis on
endotoxin stimulation in presence of 100 L volunteer serum. For
serum taken after CPB, linear regression analysis revealed sig-
nificant decline of 12.55% (95% confidence interval 11.30-13.82,
P < .0001) for every unit of concentration of patient serum on log
scale. Serum withdrawn before operation (b  0.97, 95% confi-
dence interval 2.55 to 4.50, P  .523) or control serum (b  5.25,
95% confidence interval 1.98-8.52, P  .0077) had no or negligible
influence on TNF- synthesis. Data points represent mean; error
bars represent SD.
Figure 5. No inhibition of TNF- synthesis by heparin. Whole
blood was incubated with endotoxin (10 ng/mL, S. friedenau; LPS)
for 4 hours in absence or presence of heparin (0.16-100 U/mL).
Doses that exceeded those used for CPB by 10 times did not affect
TNF- production in vitro. Bar heights represent mean for 4
independent experiments; error bars represent SD.
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vivo lipopolysaccharide-stimulated whole blood to synthe-
size TNF- as early as 30 minutes after CPB. This is in
agreement with a report describing reduced IL-2, interferon
, and TNF- production from peripheral blood mononu-
clear cells after CPB.14 Because white blood cell counts
increase during CPB, hemodilution or loss of cells synthe-
sizing TNF- is not responsible for the observed phenom-
enon. Moreover, when TNF- synthesis was normalized to
the white blood cell counts, the effect was even more
pronounced. Because TNF- production was not affected
after induction of anesthesia, it seems unlikely that drugs
used for anesthesia interfere with the ability of leukocytes to
synthesize cytokines, as has been assumed by others.20 The
finding that the expression of mRNA transcripts for TNF-
showed the same kinetics as the protein release supports the
hypothesis that the synthesis of TNF- is inhibited at a point
either preceding transcription or at the transcriptional level.
These results appear to contradict previous studies. Hattler
and coworkers21 reported enhanced TNF- mRNA-expres-
sion in isolated peripheral blood mononuclear cells in 3 of
6 patients after CPB. However, corresponding to the dimin-
ished protein secretion, all our 6 patients investigated had
markedly reduced TNF-mRNA expression in lipopolysac-
charide-activated whole blood after CPB (range 7.56%-
29.55% of preoperative values). Similar results (ie, reduced
proinflammatory cytokine expression in whole blood or
monocytes) have been observed under conditions of poly-
trauma and sepsis.12,13 A major reason for these discrepan-
cies may be that we used whole blood from our patients,
whereas in other studies isolated mononuclear cells were
studied. The latter technique necessarily included the re-
moval of serum components, such as circulating inhibitors.
Although we did not detect TNF- in unstimulated blood or
serum, some authors have measured low amounts of circu-
lating TNF-.6 This discrepancy between reduced synthesis
in whole blood and the presence of TNF- in serum from
patients after CPB may indicate that other macrophages or
endothelial or myocardial cells are the source of the sys-
Figure 6. Immune absorption of interleukin-10 does not remove
inhibitory activity from patient serum. A, Inhibitory activity in
patient serum after CPB before immune absorption is shown on
left. When IL-10 was completely removed by immune absorption
(right), serum after CPB still contained potent inhibitory activity
(P  .075 vs preoperative serum). B, Result of immune absorption
with anti-IL-10 antibodies, HLA-DR antibodies (isotype control), or
phosphate-buffered saline solution (PBS, control); n.d., not de-
tectable. Bar heights represent mean for 3 independent experi-
ments; error bars represent SD.
TABLE 3. Correlation of TNF- synthesis and circulating anti-inflammatory cytokines (n  15)
TNF- (ng/106 WBC) IL-4 (pg/mL) IL-10 (pg/mL) TGF-1 (ng/mL)
T1 0.450 0.159 106.90 63.15 36 71 17.16 12.30
T2 0.499 0.265 121.98 76.04 40 82 18.18 14.66
T3 0.381 0.258 9.78 10.48* 34 102 18.99 15.54
T4 0.109 0.105* 10.30 8.83* 29 37 14.27 10.67
T5 0.067 0.045* 11.74 9.47* 241 192* 17.44 12.74
T6 0.050 0.065* 25.97 37.59† 318 186* 22.59 13.15
T7 0.136 0.081* 48.59 27.12‡ 121 100* 16.20 13.49
T8 0.181 0.128* 60.38 68.86‡ 88 73* 8.53 8.35
T9 0.148 0.137* 36.03 40.50* 77 107 9.09 10.55
T10 0.297 0.145 78.17 72.28 41 74 10.93 12.79
T11 0.240 0.102† 123.57 103.24 50 67* 11.60 9.57
r 0.362 0.565 0.062
P value .001 .001 .460
Values are mean  SD. P values are Bonferroni adjusted and calculated as pairwise comparisons within a repeated measures nonparametric analysis
of variance model. Spearman correlation coefficient (r) was calculated versus ex vivo TNF- synthesis.
*P  .001 versus preoperative values (T1).
†P  .01 versus preoperative values (T1).
‡P  .05 versus preoperative values (T1).
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temic cytokinemia. Wan and colleagues22 pointed out that
major quantities of proinflammatory cytokines may origi-
nate from the heart after reperfusion of the ischemic myo-
cardium. These findings are also supported by previous
observation of a significant correlation between TNF-,
IL-6, and IL-8 levels and the ischemic time in patients
undergoing coronary artery bypass grafting or cardiac trans-
plantation.8,18
The endotoxin hyporesponsiveness of whole blood after
CPB could have been related to the mechanical stress ex-
erted on blood cells by foreign surfaces (shear forces) as
well as to the release of immunosuppressive mediators
during or after cardiac surgery. To test the possibility that
circulating anti-inflammatory mediators control the respon-
siveness of blood cells during and after CPB, patient serum
was tested with regard to influence on TNF- synthesis in a
heterologous whole blood system. We found that patient
serum obtained after CPB contained potent TNF--inhibi-
tory activity. This serum activity did not interfere with
endotoxin or the bioactivity of TNF-. The latter finding
excludes the possibility that soluble TNF receptors released
after CPB6 contribute to the inhibitory activity. These re-
sults and the substantial suppression of TNF- mRNA
transcripts strongly support the idea that the inhibitory ac-
tivity is targeted at cytokine synthesis and does not interfere
with the released protein.
Recently considerable interest has focused on the release
of anti-inflammatory cytokines after CPB, such as IL-4,
IL-10, and TGF-1. The involvement of these cytokines in
the endotoxin desensitization of polymorphonuclear neutro-
phils after cardiac surgery can be assumed, because they all
profoundly suppress proinflammatory cytokine synthesis in
vivo and in vitro.10,11,23-25 In accord with the data from other
groups, we found a significant release of IL-10 after
declamping7,26 and slightly elevated TGF-1 serum levels
after CPB.4 In contrast with previous studies,5 we were able
to detect IL-4 in the serum of patients after CPB. Spearman
correlation analysis revealed that IL-4 was positively but
weakly correlated with lipopolysaccharide-induced TNF-
synthesis ex vivo, and IL-10 was negatively correlated.
However, in vitro experiments demonstrated that IL-10
peak-levels in patient serum after CPB were 300-fold below
quantities of recombinant human IL-10 needed for half-
maximal TNF- inhibition in vitro. Furthermore, immune
absorption of IL-10 did not alter the inhibitory potential of
patient serum. On the basis of these results, IL-10 can be
ruled out as the main humoral factor responsible for im-
paired leukocyte function after cardiac surgery. IL-4 took a
course reverse to that of the TNF--inhibitory activity in
patient serum. TGF-1 serum concentrations were not cor-
related with TNF- production. It therefore seems unlikely
that any of these mediators contributed largely to the total
inhibitory activity in patient serum after cardiac surgery.
Some drugs commonly used in cardiac operations may
influence cytokine production and release. In vitro studies
showed that cytokine gene expression in human lipopo-
lysaccharide-stimulated and interferon -stimulated mono-
nuclear cells is inhibited by heparin.27 We therefore tested
the influence of heparin on TNF- synthesis in whole blood.
Heparin in doses 10-fold higher than those necessary for
anticoagulation during CPB did not inhibit TNF- synthesis
in vitro. Aprotinin, a serine protease inhibitor, partially
inhibits cleavage and secretion of the membrane-bound
precursor form of soluble TNF-.28 However, in recently
published studies neither the use of heparin-coated circuits
nor the administration of a high-dose regimen of aprotinin
prevented or significantly attenuated cytokine release and
neutrophil activation.29 In addition, preoperative adminis-
tration of steroids has been shown to abolish cytokine
release in heart surgery.30 Yet the patients in our examina-
tion received neither steroids nor nonsteroidal anti-inflam-
matory drugs.
A widely known in vitro and in vivo phenomenon of
endotoxin hyporesponsiveness, termed endotoxin tolerance,
is characterized by diminished synthesis of cytokines
caused by a previous contact of monocytes and macro-
phages with low amounts of lipopolysaccharide.31 Endotox-
emia as a result of bacterial translocation from the gut has
been described during CPB.32 Endotoxin tolerance could
therefore be a reason for the diminished TNF- synthesis
after CPB. Although endotoxin tolerance and the trauma
caused by CPB both result in diminished cytokine produc-
tion, the underlying mechanisms are still obscure. It should
therefore be emphasized that endotoxin tolerance differs in
various aspects from the phenomenon observed here. Usu-
ally, the development of endotoxin tolerance in humans
requires more time (3 hours) than under CPB (30 min-
utes).31 Impaired cytokine synthesis in patients after CPB is
accompanied by a markedly reduced HLA-DR expression
on monocytes,33 leading to an immunodeficient state,
whereas after induction of endotoxin tolerance no changes
of HLA-DR expression on monocytes occur, and the resis-
tance to bacterial and viral infections is enhanced. It there-
fore seems that a reduced capacity to synthesize cytokines
must not necessarily be congruent with endotoxin tolerance.
In summary, cardiac operations involving CPB lead to a
diminished lipopolysaccharide-induced TNF- synthesis in
the blood compartment. This hyporesponsiveness seems at
least in part to be controlled by currently unknown circu-
lating inhibitory activities. Because cytokines such as
TNF- are important molecules for the integrity of the host
immune response (eg, antigen presentation), this may con-
tribute to postoperative immunosuppression and to the in-
creased susceptibility to infectious complications. Further
characterization of the involved mediators and in particular
their regulation is necessary to gain a better understanding
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of the underlying pathogenesis and to develop therapeutic
strategies.
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